ATE299710T1 - Methoden zur behandlung von muskelerkrankungen und muskelstörungen - Google Patents
Methoden zur behandlung von muskelerkrankungen und muskelstörungenInfo
- Publication number
- ATE299710T1 ATE299710T1 AT94916690T AT94916690T ATE299710T1 AT E299710 T1 ATE299710 T1 AT E299710T1 AT 94916690 T AT94916690 T AT 94916690T AT 94916690 T AT94916690 T AT 94916690T AT E299710 T1 ATE299710 T1 AT E299710T1
- Authority
- AT
- Austria
- Prior art keywords
- muscle
- methods
- disorders
- treating
- diseases
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title abstract 2
- 208000029578 Muscle disease Diseases 0.000 title 1
- 208000021642 Muscular disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 210000002460 smooth muscle Anatomy 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5902293A | 1993-05-06 | 1993-05-06 | |
US08/209,204 US7115554B1 (en) | 1993-05-06 | 1994-03-08 | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
PCT/US1994/005083 WO1994026298A1 (en) | 1993-05-06 | 1994-05-06 | Methods for treating muscle diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE299710T1 true ATE299710T1 (de) | 2005-08-15 |
Family
ID=26738273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94916690T ATE299710T1 (de) | 1993-05-06 | 1994-05-06 | Methoden zur behandlung von muskelerkrankungen und muskelstörungen |
Country Status (10)
Country | Link |
---|---|
US (5) | US7115554B1 (de) |
EP (1) | EP0703785B8 (de) |
JP (3) | JP4035159B2 (de) |
KR (2) | KR100284909B1 (de) |
AT (1) | ATE299710T1 (de) |
AU (1) | AU691810B2 (de) |
CA (1) | CA2162262C (de) |
DE (1) | DE69434431T2 (de) |
ES (1) | ES2243928T3 (de) |
WO (1) | WO1994026298A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US7037888B1 (en) * | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
FR2731225B1 (fr) * | 1995-03-03 | 2003-10-31 | Pasteur Institut | Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique |
CN1651457B (zh) * | 1994-10-20 | 2010-07-28 | 巴斯德研究所 | Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列 |
DE69732711T2 (de) | 1996-07-12 | 2006-03-16 | Genentech, Inc., South San Francisco | Gamma-heregulin |
US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
DK0970207T3 (da) | 1997-02-10 | 2009-07-13 | Genentech Inc | Heregulin-varianter |
US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
EP1146893A1 (de) * | 1998-12-11 | 2001-10-24 | Tejvir S. Khurana | Von neuriten abstammende wachstumsfaktoren zur behandlung von muskeldystrophy |
AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6967102B1 (en) * | 1999-03-11 | 2005-11-22 | University Of Manitoba | Nitric oxide manipulation of muscle satellite cell activation |
US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
US7495147B2 (en) | 2000-02-28 | 2009-02-24 | Decode Genetics Ehf. | Neuregulin-1 transgenic mouse and methods of use |
CA2407656A1 (en) * | 2000-04-27 | 2001-11-08 | Kyowa Hakko Kogyo Co. Ltd. | Myocardial cell proliferation-associated genes |
EP1289553B1 (de) | 2000-05-23 | 2011-07-13 | CeNeS Pharmaceuticals, Inc. | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden |
WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
WO2004030706A2 (en) * | 2002-10-01 | 2004-04-15 | Law Peter K | Bioactive implants |
US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
RU2457854C2 (ru) * | 2005-12-30 | 2012-08-10 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед | Длительное высвобождение нейрегулина для улучшения сердечной функции |
WO2008091867A2 (en) * | 2007-01-22 | 2008-07-31 | Children's Medical Center Corporation | Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration |
CN101743474B (zh) | 2007-05-10 | 2015-06-03 | 阿索尔达治疗公司 | 检测心脏损伤的方法 |
US8354446B2 (en) | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
EP3632459A1 (de) | 2008-07-17 | 2020-04-08 | Acorda Therapeutics, Inc. | Therapeutische dosierung eines neuregulins oder einer subsequenz davon zur behandlung oder prophylaxe von herzversagen |
CN107041949A (zh) | 2008-08-15 | 2017-08-15 | 阿索尔达治疗公司 | 在cns神经性损伤后非‑急性期间处理的组合物及方法 |
WO2010060265A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin peptides and their use |
US20120121557A1 (en) * | 2009-07-22 | 2012-05-17 | Children's Medical Center Corporation | Neuregulin induced proliferation of cardiomyocytes |
JP2013529911A (ja) * | 2010-05-28 | 2013-07-25 | マインド−エヌアールジー ソシエテ アノニム | ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法 |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
BR112015029293A2 (pt) | 2013-05-22 | 2018-04-24 | Zensun Shanghai Science & Tech Ltd | método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero |
KR102051433B1 (ko) * | 2013-08-27 | 2020-01-08 | (주)네오팜 | 근육 분화 촉진 및 근육 강화용 조성물 및 외용제 |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
EP3094323A4 (de) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Verfahren und zusammensetzungen zur modulierung von hormonspiegeln |
CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
WO2021052277A1 (zh) | 2019-09-16 | 2021-03-25 | 上海泽生科技开发股份有限公司 | 重组人神经调节蛋白衍生物及其用途 |
CN113289002A (zh) | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
EP4351722A1 (de) | 2021-06-10 | 2024-04-17 | Amgen Inc. | Manipulierte nrg-1-varianten mit verbesserter selektivität gegenüber erbb4 aber nicht gegen erbb3 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5143842A (en) * | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
DE69031120T2 (de) | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
US5464751A (en) | 1990-04-06 | 1995-11-07 | Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
WO1991018921A1 (en) | 1990-05-25 | 1991-12-12 | Georgetown University | GROWTH FACTOR WHICH INHIBITS THE GROWTH OF CELLS OVEREXPRESSING THE HUMAN ONCOGENE erbB-2 |
CA2086264C (en) | 1990-06-27 | 2002-12-24 | Jeffrey L. Browning | Surface complexed lymphotoxin |
KR930703359A (ko) | 1991-01-14 | 1993-11-29 | 조지 알. 라스니어 | 이알비비- 2(erbB-2) 수용체 단백질에 결합하고 세포 반응을 유도하는 리간드 성장인자 |
US5530109A (en) * | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
-
1994
- 1994-03-08 US US08/209,204 patent/US7115554B1/en not_active Expired - Lifetime
- 1994-05-06 JP JP52559394A patent/JP4035159B2/ja not_active Expired - Lifetime
- 1994-05-06 AT AT94916690T patent/ATE299710T1/de not_active IP Right Cessation
- 1994-05-06 DE DE69434431T patent/DE69434431T2/de not_active Expired - Lifetime
- 1994-05-06 KR KR1019950704903A patent/KR100284909B1/ko not_active IP Right Cessation
- 1994-05-06 CA CA2162262A patent/CA2162262C/en not_active Expired - Lifetime
- 1994-05-06 AU AU68278/94A patent/AU691810B2/en not_active Expired
- 1994-05-06 EP EP94916690A patent/EP0703785B8/de not_active Expired - Lifetime
- 1994-05-06 WO PCT/US1994/005083 patent/WO1994026298A1/en active IP Right Grant
- 1994-05-06 ES ES94916690T patent/ES2243928T3/es not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/468,731 patent/US7384756B1/en active Active
- 1995-06-06 US US08/467,602 patent/US6444642B1/en not_active Expired - Lifetime
-
2000
- 2000-09-14 KR KR1020000054080A patent/KR100306244B1/ko not_active IP Right Cessation
-
2003
- 2003-04-30 JP JP2003125885A patent/JP4018028B2/ja not_active Expired - Lifetime
-
2007
- 2007-08-03 JP JP2007203508A patent/JP2007332153A/ja active Pending
-
2008
- 2008-06-10 US US12/157,614 patent/US7718606B2/en not_active Expired - Fee Related
-
2010
- 2010-05-17 US US12/781,633 patent/US8026213B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR100284909B1 (ko) | 2001-03-15 |
US6444642B1 (en) | 2002-09-03 |
EP0703785A1 (de) | 1996-04-03 |
US7384756B1 (en) | 2008-06-10 |
US8026213B2 (en) | 2011-09-27 |
US7115554B1 (en) | 2006-10-03 |
EP0703785A4 (de) | 1998-12-30 |
DE69434431T2 (de) | 2006-05-24 |
EP0703785B8 (de) | 2005-09-14 |
US20110144015A1 (en) | 2011-06-16 |
US20090018073A1 (en) | 2009-01-15 |
WO1994026298A1 (en) | 1994-11-24 |
KR100306244B1 (ko) | 2001-09-24 |
CA2162262A1 (en) | 1994-11-24 |
AU691810B2 (en) | 1998-05-28 |
JPH11507201A (ja) | 1999-06-29 |
DE69434431D1 (de) | 2005-08-25 |
EP0703785B1 (de) | 2005-07-20 |
AU6827894A (en) | 1994-12-12 |
US7718606B2 (en) | 2010-05-18 |
JP2007332153A (ja) | 2007-12-27 |
CA2162262C (en) | 2011-07-12 |
JP4018028B2 (ja) | 2007-12-05 |
JP2004043437A (ja) | 2004-02-12 |
JP4035159B2 (ja) | 2008-01-16 |
ES2243928T3 (es) | 2005-12-01 |
KR960702318A (ko) | 1996-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE299710T1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE69521700D1 (de) | Mittel und methoden zur behandlung von plaque-krankheiten | |
DE69232485T2 (de) | VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten. | |
ATE110958T1 (de) | Verwendung von sertralin zur behandlung verfrühter ejakulation. | |
ATE390917T1 (de) | Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten | |
DE69838882D1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
DE69621786T2 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
DE69626916D1 (de) | Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten | |
ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
ATE230263T1 (de) | At1 rezeptor antagonist zur anregung von apoptosis | |
ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
DE689838T1 (de) | Verwendung von Diademosim 5',5'''-p1,p4-Tetraphosphat zur Behandlung von ischämischen Myokard-Erkrankungen | |
DE69424415T2 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
DE69530600D1 (de) | Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung | |
MX9602793A (es) | Uso de sertralina para tratar pacientes despues de un infarto de miocardio. | |
BG102009A (en) | Method for the treatment of manic and two-pole disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |